Duvelisib

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 204 publications

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Dual PI3Kδ/γ inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS-STING-type I interferon signaling.

Journal: Biochemical and biophysical research communications
Published: December 01, 2025

A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.

A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.

Journal: European journal of haematology
Published: August 22, 2025

Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics.

Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics.

Journal: Cureus
Published: August 18, 2025

Enantiomeric separation of duvelisib by Electrokinetic Chromatography. Application to the analysis of pharmaceutical formulations and determination in serum and wastewater samples previous μSPEed preconcentration.

Enantiomeric separation of duvelisib by Electrokinetic Chromatography. Application to the analysis of pharmaceutical formulations and determination in serum and wastewater samples previous μSPEed preconcentration.

Journal: Talanta
Published: August 15, 2025

Endpoint Exposure-Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials.

Endpoint Exposure-Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials.

Journal: Clinical pharmacology and therapeutics
Published: July 21, 2025

Human Serum Albumin-Lipid Nanocapsules of Duvelisib for Hematological Cancers: Characterization, In-Vitro Cell-Culture, Toxicity and Pharmacokinetic Studies.

Human Serum Albumin-Lipid Nanocapsules of Duvelisib for Hematological Cancers: Characterization, In-Vitro Cell-Culture, Toxicity and Pharmacokinetic Studies.

Journal: AAPS PharmSciTech
Published: June 21, 2025

Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies.

Dermatologic Adverse Events in Patients Receiving Duvelisib Single-Agent and Combination Therapies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: May 23, 2025

Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.

Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.

Journal: Cell death discovery
Published: May 21, 2025

Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma.

Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma.

Journal: Apoptosis : an international journal on programmed cell death
Published: March 28, 2025

A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects.

A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects.

Journal: American journal of cancer research
Published: March 20, 2025

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.

Journal: Journal of cutaneous medicine and surgery
Published: March 12, 2025

Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.

Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.

Journal: Blood advances
Published: March 10, 2025
Showing 1-12 of 204

Last Updated: 02/24/2026